Recent studies have revealed that CDX2 is aberrantly expressed in gastric cancer, colorectal cancer, thyroid cancer, ovarian cancer, endometrial adenocarcinoma, bladder and prostate adenocarcinoma [26, 27]. This evidence concerns the gene CDX2 and thyroid gland carcinoma.